Serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic HCV genotype 1b infection

Hepatitis Monthly

Volumn 13, Issue 5, 2013, Pages

  Aizawa, Yoshio ^a   Shimada, Noritomo ^b   Abe, Hiroshi ^a   Seki, Nobuyoshi ^a   Aida, Yuta ^a   Ishiguro, Haruya ^a   Ika, Makiko ^b   Kato, Keizo ^b   Tsubota, Akihito ^c  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shinmatsudo Central General Hospital   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chromatography; Hepatitis C; High pressure liquid; Lipoproteins; Lipoproteins VLDL; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ARGININE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 28; LOW DENSITY LIPOPROTEIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84881234591     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.8988     Document Type: Article

References (33)

1. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab. 2010;21(1):33-40.
2. Heaton NS, Randall G. Multifaceted roles for lipids in viral infec-tion. Trends Microbiol. 2011;19(7):368-75.
3. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Jr., et al. Hepatitis C virus production by human hepatocytes dependent on assem-bly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A. 2007;104(14):5848-53.
4. Scholtes C, Ramiere C, Rainteau D, Perrin-Cocon L, Wolf C, Hum-bert L, et al. High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. Hepa-tology. 2012;56(1):39-48.
5. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol. 2006;80(5):2418-28.
6. Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of li-poproteins and cellular receptors. J Gen Virol. 2009;90(Pt 5):1055-70.
7. Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology. 2006;44(2):335-40.
8. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginter-feron plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitu-tions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007;46(3):403-10.
9. Economou M, Milionis H, Filis S, Baltayiannis G, Christou L, Elisaf M, et al. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol. 2008;23(4):586-91.
10. Hsu CS, Liu CH, Liu CJ, Wang CC, Chen CL, Lai MY, et al. Associa-tion of lipid profiles with hepatitis C viral load in chronic hepa-titis C patients with genotype 1 or 2 infection. Am J Gastroenterol. 2009;104(3):598-604.
11. Zampino R, Ingrosso D, Durante-Mangoni E, Capasso R, Tripodi MF, Restivo L, et al. Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver ac-cumulation in HCV genotype 3 infected patients. J Viral Hepat. 2008;15(10):740-6.
12. Sheridan DA, Price DA, Schmid ML, Toms GL, Donaldson P, Neely D, et al. Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavi-rin. Aliment Pharmacol Ther. 2009;29(12):1282-90.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the con-centration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
14. Margolis J, Kenrick KG. Polyacrylamide gel electrophore-sis in a continuous molecular sieve gradient. Anal Biochem. 1968;25(1):347-62.
15. Steim JM, Edner OJ, Bargoot FG. Structure of human serum li-poproteins: nuclear magnetic resonance supports a micellar model. Science. 1968;162(3856):909-11.
16. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and tri-glycerides in lipoproteins by HPLC. J Lipid Res. 2002;43(5):805-14.
17. Okazaki M, Usui S, Ishigami M, Sakai N, Nakamura T, Matsuzawa Y, et al. Identification of unique lipoprotein subclasses for vis-ceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol. 2005;25(3):578-84.
18. Van den Eynde E, Crespo M, Esteban JI, Jardi R, Ribera E, Carbonell J, et al. Response-guided therapy for chronic hepatitis C virus in-fection in patients coinfected with HIV: a pilot trial. Clin Infect Dis. 2009;48(8):1152-9.
19. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, man-agement, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. T.e METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-93.
21. Aizawa Y, Yohizawa K, Aida Y, Ishiguro H, Abe H, Tsubota A. Geno-type rs8099917 near the IL28B gene and amino acid substitu-tion at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C. Mol Cell Biochem. 2012;360(1-2):9-14.
22. Blaising J, Pecheur EI. Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies. Biochimie. 2013;95(1):96-102.
23. Sheridan DA, Neely RD, Bassendine MF. Hepatitis C virus and lip-ids in the era of direct acting antivirals (DAAs). Clin Res Hepatol Gastroenterol. 2012.
24. Aizawa Y, Abe H. Viral Factors Associated With Response to An-tiviral Therapy for Chronic Hepatitis C Virus Infection. J Antivir Antiretrovir S. 2012;3:3.
25. Usui S, Mizuno T, Okazaki M, Nakamura M, Sakurabayashi I. Evaluation of a gel-permeation high-performance liquid chro-matography for determining triglyceride levels in serum major lipoproteins, compared with the ultracentrifugation/precipita-tion method. Clin Biochem. 2009;42(1-2):114-7.
26. Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology. 2010;52(3):854-63.
27. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-in-duced viral clearance. Nature. 2009;461(7262):399-401.
28. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Saka-moto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105-9.
29. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, et al. Interferon-lambda genotype and low serum low-density lipo-protein cholesterol levels in patients with chronic hepatitis C infection. Hepatology. 2010;51(6):1904-11.
30. Clark PJ, Thompson AJ, Zhu M, Vock DM, Zhu Q, Ge D, et al. In-terleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the as-sociation between LDL-C and treatment response. J Viral Hepat. 2012;19(5):332-40.
31. Mawatari H, Yoneda M, Fujita K, Nozaki Y, Shinohara Y, Sasaki H, et al. Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b. J Viral Hepat. 2010;17(4):274-9.
32. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, et al. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes. 1998;47(5):779-87.
33. Perrin-Cocon L, Diaz O, Andre P, Lotteau V. Modified lipoproteinsprovide lipids that modulate dendritic cell immune function.Biochimie. 2013;95(1):103-8.